国家卫健委将启动抗癌药国家集中采购、医保准入谈判

2018-04-28 佚名 国新发布

国务院新闻办新闻发布会上,曾益新强调,启动抗癌药品国家集中采购、医保准入谈判。

今日(4月28日),国务院新闻办举行新闻发布会,国家卫生健康委员会副主任曾益新和人力资源社会保障部有关负责同志介绍降低抗癌药品费用有关情况。曾益新表示,随着我国人口老龄化和工业化、城镇化进程不断加快,癌症已成为威胁人民群众生命健康的“头号杀手”,发病率和死亡率呈现“双升”态势,防控形势十分严峻。党中央、国务院始终高度重视人民健康。习近平总书记在党的十九大报告中确立了实施健康中国重大战略,作出了健全药品供应保障制度的重大部署。

曾益新表示,今年国务院常务会议明确了包括降关税、加快创新药进口上市、加强知识产权保护、强化质量监管、综合措施让群众切实感受到急需抗癌药品价格有明显降低等要求,从多环节、多渠道降低抗癌药品费用。4月20日,国务院领导又主持召开专题会议,研究部署具体措施。国家卫生健康委员会会同有关部门按照“政府主导、政策联动、规范持续”的原则,在降低税率的基础上,综合运用集中采购、医保支付、合理用药、研发创新等联动措施,完善抗癌药品供应保障政策,制订了一系列工作措施。坚持以人民健康为中心,既有近期措施,也有长期考虑,陆续推动落地,形成协同作用,有利于坚持以药品临床为中心的价值导向、深化医药供给侧结构性改革,有利于激发市场活力、完善抗癌药品供应保障,有利于减轻癌症患者药费负担、放大政策惠民效果。

曾益新强调,近期重点工作是5月1日正式实施进口药品零关税后,启动抗癌药品国家集中采购、医保准入谈判:对已纳入基本医保药品目录的抗癌药品,3家以上企业生产的品种拟开展专项集中招标;生产企业不满3家的品种通过谈判、撮合等多种方式,鼓励形成全国统一的采购价格;对尚未纳入医保报销的抗癌药品,组织专家评审并开展准入谈判,将符合条件的药品纳入医保药品目录范围。

推动建立控制抗癌药费负担的长效机制。一是鼓励研发创新。加大国家科技计划对抗癌药品研发的支持力度,建立对于国产抗癌药品研发的持续稳定支持机制,完善国家新药研发体系,提升国家新药创新能力。对于临床急需的抗癌药品,优先支持研发,鼓励抗癌新靶点、新机制药品的研究和原始创新,鼓励专利到期或即将到期的急需抗癌药品的仿制研究,提高药品选择性。二是加快癌症防治药品的审批上市。加快落实中办、国办《关于深化审评审批制度改革鼓励药品医疗器械创新的意见》,提高审评能力,科学简化审批手续,加快癌症防治药品的上市。比如,前期媒体比较关注的九价宫颈癌疫苗(人乳头瘤病毒疫苗,HPV),药监部门目前正在加快工作进度,力争早日批准上市。三是降低药品流通成本。严厉打击商业贿赂、价格垄断等违法违规行为。今年内全面推开药品“两票制”使流通环节加价更加透明,挤压价格虚高水分。四是提升诊疗能力和合理使用抗癌药品。坚持临床价值导向,加强对临床用药的检查指导,制定完善癌症临床路径和并加快实施,促进癌症规范化诊疗;推广癌症临床用药指南,落实药师处方审核及临床用药指导工作,提升合理用药水平。

曾益新称,各部门按照任务分工抓好组织实施,强化政策联动,细化政策措施,明确工作要求,建立长效工作机制,全面推动各项工作落实。加强政策宣传,广泛宣传抗癌药品供应保障的主要政策措施和重要意义,有针对性地做好抗癌药品临床使用的科普工作,积极回应、妥善处理公众关心的抗癌药品问题,全面做好抗癌药品供应保障工作。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=310693, encodeId=15bf31069335, content=vghhhhhh, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0171930782, createdName=为你把脉, createdTime=Mon Apr 30 09:48:13 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1258344, encodeId=a1b1125834466, content=<a href='/topic/show?id=b0ae365e02f' target=_blank style='color:#2F92EE;'>#卫健委#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36570, encryptionId=b0ae365e02f, topicName=卫健委)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Mon Apr 30 08:32:00 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291039, encodeId=9d2c1291039ae, content=<a href='/topic/show?id=e53140859f6' target=_blank style='color:#2F92EE;'>#国家卫健委#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40859, encryptionId=e53140859f6, topicName=国家卫健委)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba5f232, createdName=zhao4616, createdTime=Mon Apr 30 08:32:00 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314752, encodeId=a5cf1314e5271, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Apr 30 08:32:00 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460096, encodeId=6107146009608, content=<a href='/topic/show?id=cb9d98e23ee' target=_blank style='color:#2F92EE;'>#集中采购#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98723, encryptionId=cb9d98e23ee, topicName=集中采购)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1406243727, createdName=liuxiaona, createdTime=Mon Apr 30 08:32:00 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1532736, encodeId=1a101532e36a6, content=<a href='/topic/show?id=88f395665de' target=_blank style='color:#2F92EE;'>#采购#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95665, encryptionId=88f395665de, topicName=采购)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bb312387914, createdName=wolongzxh, createdTime=Mon Apr 30 08:32:00 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=310432, encodeId=979c310432dc, content=vbbhhhhh, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0171930782, createdName=为你把脉, createdTime=Sun Apr 29 17:00:20 CST 2018, time=2018-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=310150, encodeId=43f9310150b9, content=加大谈判监管力度.确保药真价实., beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sat Apr 28 18:32:14 CST 2018, time=2018-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=310146, encodeId=e9f1310146f5, content=VB哈哈哈还好还好哈, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0171930782, createdName=为你把脉, createdTime=Sat Apr 28 17:37:55 CST 2018, time=2018-04-28, status=1, ipAttribution=)]
    2018-04-30 为你把脉

    vghhhhhh

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=310693, encodeId=15bf31069335, content=vghhhhhh, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0171930782, createdName=为你把脉, createdTime=Mon Apr 30 09:48:13 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1258344, encodeId=a1b1125834466, content=<a href='/topic/show?id=b0ae365e02f' target=_blank style='color:#2F92EE;'>#卫健委#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36570, encryptionId=b0ae365e02f, topicName=卫健委)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Mon Apr 30 08:32:00 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291039, encodeId=9d2c1291039ae, content=<a href='/topic/show?id=e53140859f6' target=_blank style='color:#2F92EE;'>#国家卫健委#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40859, encryptionId=e53140859f6, topicName=国家卫健委)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba5f232, createdName=zhao4616, createdTime=Mon Apr 30 08:32:00 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314752, encodeId=a5cf1314e5271, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Apr 30 08:32:00 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460096, encodeId=6107146009608, content=<a href='/topic/show?id=cb9d98e23ee' target=_blank style='color:#2F92EE;'>#集中采购#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98723, encryptionId=cb9d98e23ee, topicName=集中采购)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1406243727, createdName=liuxiaona, createdTime=Mon Apr 30 08:32:00 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1532736, encodeId=1a101532e36a6, content=<a href='/topic/show?id=88f395665de' target=_blank style='color:#2F92EE;'>#采购#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95665, encryptionId=88f395665de, topicName=采购)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bb312387914, createdName=wolongzxh, createdTime=Mon Apr 30 08:32:00 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=310432, encodeId=979c310432dc, content=vbbhhhhh, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0171930782, createdName=为你把脉, createdTime=Sun Apr 29 17:00:20 CST 2018, time=2018-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=310150, encodeId=43f9310150b9, content=加大谈判监管力度.确保药真价实., beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sat Apr 28 18:32:14 CST 2018, time=2018-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=310146, encodeId=e9f1310146f5, content=VB哈哈哈还好还好哈, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0171930782, createdName=为你把脉, createdTime=Sat Apr 28 17:37:55 CST 2018, time=2018-04-28, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=310693, encodeId=15bf31069335, content=vghhhhhh, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0171930782, createdName=为你把脉, createdTime=Mon Apr 30 09:48:13 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1258344, encodeId=a1b1125834466, content=<a href='/topic/show?id=b0ae365e02f' target=_blank style='color:#2F92EE;'>#卫健委#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36570, encryptionId=b0ae365e02f, topicName=卫健委)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Mon Apr 30 08:32:00 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291039, encodeId=9d2c1291039ae, content=<a href='/topic/show?id=e53140859f6' target=_blank style='color:#2F92EE;'>#国家卫健委#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40859, encryptionId=e53140859f6, topicName=国家卫健委)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba5f232, createdName=zhao4616, createdTime=Mon Apr 30 08:32:00 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314752, encodeId=a5cf1314e5271, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Apr 30 08:32:00 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460096, encodeId=6107146009608, content=<a href='/topic/show?id=cb9d98e23ee' target=_blank style='color:#2F92EE;'>#集中采购#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98723, encryptionId=cb9d98e23ee, topicName=集中采购)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1406243727, createdName=liuxiaona, createdTime=Mon Apr 30 08:32:00 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1532736, encodeId=1a101532e36a6, content=<a href='/topic/show?id=88f395665de' target=_blank style='color:#2F92EE;'>#采购#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95665, encryptionId=88f395665de, topicName=采购)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bb312387914, createdName=wolongzxh, createdTime=Mon Apr 30 08:32:00 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=310432, encodeId=979c310432dc, content=vbbhhhhh, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0171930782, createdName=为你把脉, createdTime=Sun Apr 29 17:00:20 CST 2018, time=2018-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=310150, encodeId=43f9310150b9, content=加大谈判监管力度.确保药真价实., beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sat Apr 28 18:32:14 CST 2018, time=2018-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=310146, encodeId=e9f1310146f5, content=VB哈哈哈还好还好哈, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0171930782, createdName=为你把脉, createdTime=Sat Apr 28 17:37:55 CST 2018, time=2018-04-28, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=310693, encodeId=15bf31069335, content=vghhhhhh, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0171930782, createdName=为你把脉, createdTime=Mon Apr 30 09:48:13 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1258344, encodeId=a1b1125834466, content=<a href='/topic/show?id=b0ae365e02f' target=_blank style='color:#2F92EE;'>#卫健委#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36570, encryptionId=b0ae365e02f, topicName=卫健委)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Mon Apr 30 08:32:00 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291039, encodeId=9d2c1291039ae, content=<a href='/topic/show?id=e53140859f6' target=_blank style='color:#2F92EE;'>#国家卫健委#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40859, encryptionId=e53140859f6, topicName=国家卫健委)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba5f232, createdName=zhao4616, createdTime=Mon Apr 30 08:32:00 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314752, encodeId=a5cf1314e5271, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Apr 30 08:32:00 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460096, encodeId=6107146009608, content=<a href='/topic/show?id=cb9d98e23ee' target=_blank style='color:#2F92EE;'>#集中采购#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98723, encryptionId=cb9d98e23ee, topicName=集中采购)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1406243727, createdName=liuxiaona, createdTime=Mon Apr 30 08:32:00 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1532736, encodeId=1a101532e36a6, content=<a href='/topic/show?id=88f395665de' target=_blank style='color:#2F92EE;'>#采购#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95665, encryptionId=88f395665de, topicName=采购)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bb312387914, createdName=wolongzxh, createdTime=Mon Apr 30 08:32:00 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=310432, encodeId=979c310432dc, content=vbbhhhhh, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0171930782, createdName=为你把脉, createdTime=Sun Apr 29 17:00:20 CST 2018, time=2018-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=310150, encodeId=43f9310150b9, content=加大谈判监管力度.确保药真价实., beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sat Apr 28 18:32:14 CST 2018, time=2018-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=310146, encodeId=e9f1310146f5, content=VB哈哈哈还好还好哈, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0171930782, createdName=为你把脉, createdTime=Sat Apr 28 17:37:55 CST 2018, time=2018-04-28, status=1, ipAttribution=)]
    2018-04-30 sunylz
  5. [GetPortalCommentsPageByObjectIdResponse(id=310693, encodeId=15bf31069335, content=vghhhhhh, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0171930782, createdName=为你把脉, createdTime=Mon Apr 30 09:48:13 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1258344, encodeId=a1b1125834466, content=<a href='/topic/show?id=b0ae365e02f' target=_blank style='color:#2F92EE;'>#卫健委#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36570, encryptionId=b0ae365e02f, topicName=卫健委)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Mon Apr 30 08:32:00 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291039, encodeId=9d2c1291039ae, content=<a href='/topic/show?id=e53140859f6' target=_blank style='color:#2F92EE;'>#国家卫健委#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40859, encryptionId=e53140859f6, topicName=国家卫健委)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba5f232, createdName=zhao4616, createdTime=Mon Apr 30 08:32:00 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314752, encodeId=a5cf1314e5271, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Apr 30 08:32:00 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460096, encodeId=6107146009608, content=<a href='/topic/show?id=cb9d98e23ee' target=_blank style='color:#2F92EE;'>#集中采购#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98723, encryptionId=cb9d98e23ee, topicName=集中采购)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1406243727, createdName=liuxiaona, createdTime=Mon Apr 30 08:32:00 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1532736, encodeId=1a101532e36a6, content=<a href='/topic/show?id=88f395665de' target=_blank style='color:#2F92EE;'>#采购#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95665, encryptionId=88f395665de, topicName=采购)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bb312387914, createdName=wolongzxh, createdTime=Mon Apr 30 08:32:00 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=310432, encodeId=979c310432dc, content=vbbhhhhh, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0171930782, createdName=为你把脉, createdTime=Sun Apr 29 17:00:20 CST 2018, time=2018-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=310150, encodeId=43f9310150b9, content=加大谈判监管力度.确保药真价实., beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sat Apr 28 18:32:14 CST 2018, time=2018-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=310146, encodeId=e9f1310146f5, content=VB哈哈哈还好还好哈, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0171930782, createdName=为你把脉, createdTime=Sat Apr 28 17:37:55 CST 2018, time=2018-04-28, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=310693, encodeId=15bf31069335, content=vghhhhhh, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0171930782, createdName=为你把脉, createdTime=Mon Apr 30 09:48:13 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1258344, encodeId=a1b1125834466, content=<a href='/topic/show?id=b0ae365e02f' target=_blank style='color:#2F92EE;'>#卫健委#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36570, encryptionId=b0ae365e02f, topicName=卫健委)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Mon Apr 30 08:32:00 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291039, encodeId=9d2c1291039ae, content=<a href='/topic/show?id=e53140859f6' target=_blank style='color:#2F92EE;'>#国家卫健委#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40859, encryptionId=e53140859f6, topicName=国家卫健委)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba5f232, createdName=zhao4616, createdTime=Mon Apr 30 08:32:00 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314752, encodeId=a5cf1314e5271, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Apr 30 08:32:00 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460096, encodeId=6107146009608, content=<a href='/topic/show?id=cb9d98e23ee' target=_blank style='color:#2F92EE;'>#集中采购#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98723, encryptionId=cb9d98e23ee, topicName=集中采购)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1406243727, createdName=liuxiaona, createdTime=Mon Apr 30 08:32:00 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1532736, encodeId=1a101532e36a6, content=<a href='/topic/show?id=88f395665de' target=_blank style='color:#2F92EE;'>#采购#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95665, encryptionId=88f395665de, topicName=采购)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bb312387914, createdName=wolongzxh, createdTime=Mon Apr 30 08:32:00 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=310432, encodeId=979c310432dc, content=vbbhhhhh, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0171930782, createdName=为你把脉, createdTime=Sun Apr 29 17:00:20 CST 2018, time=2018-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=310150, encodeId=43f9310150b9, content=加大谈判监管力度.确保药真价实., beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sat Apr 28 18:32:14 CST 2018, time=2018-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=310146, encodeId=e9f1310146f5, content=VB哈哈哈还好还好哈, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0171930782, createdName=为你把脉, createdTime=Sat Apr 28 17:37:55 CST 2018, time=2018-04-28, status=1, ipAttribution=)]
    2018-04-30 wolongzxh
  7. [GetPortalCommentsPageByObjectIdResponse(id=310693, encodeId=15bf31069335, content=vghhhhhh, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0171930782, createdName=为你把脉, createdTime=Mon Apr 30 09:48:13 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1258344, encodeId=a1b1125834466, content=<a href='/topic/show?id=b0ae365e02f' target=_blank style='color:#2F92EE;'>#卫健委#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36570, encryptionId=b0ae365e02f, topicName=卫健委)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Mon Apr 30 08:32:00 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291039, encodeId=9d2c1291039ae, content=<a href='/topic/show?id=e53140859f6' target=_blank style='color:#2F92EE;'>#国家卫健委#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40859, encryptionId=e53140859f6, topicName=国家卫健委)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba5f232, createdName=zhao4616, createdTime=Mon Apr 30 08:32:00 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314752, encodeId=a5cf1314e5271, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Apr 30 08:32:00 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460096, encodeId=6107146009608, content=<a href='/topic/show?id=cb9d98e23ee' target=_blank style='color:#2F92EE;'>#集中采购#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98723, encryptionId=cb9d98e23ee, topicName=集中采购)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1406243727, createdName=liuxiaona, createdTime=Mon Apr 30 08:32:00 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1532736, encodeId=1a101532e36a6, content=<a href='/topic/show?id=88f395665de' target=_blank style='color:#2F92EE;'>#采购#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95665, encryptionId=88f395665de, topicName=采购)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bb312387914, createdName=wolongzxh, createdTime=Mon Apr 30 08:32:00 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=310432, encodeId=979c310432dc, content=vbbhhhhh, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0171930782, createdName=为你把脉, createdTime=Sun Apr 29 17:00:20 CST 2018, time=2018-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=310150, encodeId=43f9310150b9, content=加大谈判监管力度.确保药真价实., beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sat Apr 28 18:32:14 CST 2018, time=2018-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=310146, encodeId=e9f1310146f5, content=VB哈哈哈还好还好哈, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0171930782, createdName=为你把脉, createdTime=Sat Apr 28 17:37:55 CST 2018, time=2018-04-28, status=1, ipAttribution=)]
    2018-04-29 为你把脉

    vbbhhhhh

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=310693, encodeId=15bf31069335, content=vghhhhhh, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0171930782, createdName=为你把脉, createdTime=Mon Apr 30 09:48:13 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1258344, encodeId=a1b1125834466, content=<a href='/topic/show?id=b0ae365e02f' target=_blank style='color:#2F92EE;'>#卫健委#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36570, encryptionId=b0ae365e02f, topicName=卫健委)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Mon Apr 30 08:32:00 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291039, encodeId=9d2c1291039ae, content=<a href='/topic/show?id=e53140859f6' target=_blank style='color:#2F92EE;'>#国家卫健委#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40859, encryptionId=e53140859f6, topicName=国家卫健委)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba5f232, createdName=zhao4616, createdTime=Mon Apr 30 08:32:00 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314752, encodeId=a5cf1314e5271, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Apr 30 08:32:00 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460096, encodeId=6107146009608, content=<a href='/topic/show?id=cb9d98e23ee' target=_blank style='color:#2F92EE;'>#集中采购#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98723, encryptionId=cb9d98e23ee, topicName=集中采购)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1406243727, createdName=liuxiaona, createdTime=Mon Apr 30 08:32:00 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1532736, encodeId=1a101532e36a6, content=<a href='/topic/show?id=88f395665de' target=_blank style='color:#2F92EE;'>#采购#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95665, encryptionId=88f395665de, topicName=采购)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bb312387914, createdName=wolongzxh, createdTime=Mon Apr 30 08:32:00 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=310432, encodeId=979c310432dc, content=vbbhhhhh, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0171930782, createdName=为你把脉, createdTime=Sun Apr 29 17:00:20 CST 2018, time=2018-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=310150, encodeId=43f9310150b9, content=加大谈判监管力度.确保药真价实., beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sat Apr 28 18:32:14 CST 2018, time=2018-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=310146, encodeId=e9f1310146f5, content=VB哈哈哈还好还好哈, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0171930782, createdName=为你把脉, createdTime=Sat Apr 28 17:37:55 CST 2018, time=2018-04-28, status=1, ipAttribution=)]
    2018-04-28 1e0f8808m18(暂无匿称)

    加大谈判监管力度.确保药真价实.

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=310693, encodeId=15bf31069335, content=vghhhhhh, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0171930782, createdName=为你把脉, createdTime=Mon Apr 30 09:48:13 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1258344, encodeId=a1b1125834466, content=<a href='/topic/show?id=b0ae365e02f' target=_blank style='color:#2F92EE;'>#卫健委#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36570, encryptionId=b0ae365e02f, topicName=卫健委)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Mon Apr 30 08:32:00 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291039, encodeId=9d2c1291039ae, content=<a href='/topic/show?id=e53140859f6' target=_blank style='color:#2F92EE;'>#国家卫健委#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40859, encryptionId=e53140859f6, topicName=国家卫健委)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba5f232, createdName=zhao4616, createdTime=Mon Apr 30 08:32:00 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314752, encodeId=a5cf1314e5271, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Apr 30 08:32:00 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460096, encodeId=6107146009608, content=<a href='/topic/show?id=cb9d98e23ee' target=_blank style='color:#2F92EE;'>#集中采购#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98723, encryptionId=cb9d98e23ee, topicName=集中采购)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1406243727, createdName=liuxiaona, createdTime=Mon Apr 30 08:32:00 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1532736, encodeId=1a101532e36a6, content=<a href='/topic/show?id=88f395665de' target=_blank style='color:#2F92EE;'>#采购#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95665, encryptionId=88f395665de, topicName=采购)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bb312387914, createdName=wolongzxh, createdTime=Mon Apr 30 08:32:00 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=310432, encodeId=979c310432dc, content=vbbhhhhh, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0171930782, createdName=为你把脉, createdTime=Sun Apr 29 17:00:20 CST 2018, time=2018-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=310150, encodeId=43f9310150b9, content=加大谈判监管力度.确保药真价实., beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sat Apr 28 18:32:14 CST 2018, time=2018-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=310146, encodeId=e9f1310146f5, content=VB哈哈哈还好还好哈, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0171930782, createdName=为你把脉, createdTime=Sat Apr 28 17:37:55 CST 2018, time=2018-04-28, status=1, ipAttribution=)]
    2018-04-28 为你把脉

    VB哈哈哈还好还好哈

    0

相关资讯

进口抗癌药“零关税” 患者受益几多

5月1日起,我国实际进口的全部抗癌药将实现零关税。这个大好消息,从上周开始就在病友间广为传播。在医院药房,近来已有患者家属咨询,“零关税”后药价会下降多少?河南省患者何时能享受到这个福利?对于恶性肿瘤患者而言,除了零关税以外,还有哪些政策将影响到他们的医疗支出?针对这些问题,记者走访了相关医院、专家,以及患者和家属。现状 因价格原因,河南省癌症患者目前倾向国产药根据国家癌症中心发布的数据,我国每年

JCO:无RCT证据支持的药物也会被批准上市么?FDA批准的无RCT证据支持的抗癌药上市后会存在哪些隐患?

在没有随机对照临床试验(RCT)证据支持的条件下,仍然会有抗癌药物被FDA批准上市,尤其是在某些罕见病和尚无有效疗法的疾病中比较常见。这其中的隐患是,上市前并没有充分的数据对药物疗效和安全性进行验证,伴随的问题则往往是在药物上市后才会发现某些严重的甚至致命的不良反应,此时势必会对药物标签进行修正。

进口抗癌药将零关税 专家估算或降价20%

国务院常务会议日前明确,从今年5月1日起,将包括抗癌药在内的所有普通药品、具有抗癌作用的生物类药品及有实际进口的中成药进口关税降至零,使我国实际进口的全部抗癌药实现零关税。有专家估算,在多措并举下,进口抗癌药价格有望降价20%。据相关数据显示,恶性肿瘤已经上升到人类死因的首位,我国每年恶性肿瘤新发病例430万,每天有1万多人死于恶性肿瘤。恶性肿瘤已经成为严重危害人民健康的常见疾病。进口抗癌药

李克强:进口抗癌药仅降到“零关税”还不够

在今年两会总理记者会上作出“抗癌药品进口税率力争降到零税率”承诺短短20多天后,李克强总理4月12日主持召开国务院常务会议,决定对进口抗癌药实施零关税并鼓励创新药进口。“进口抗癌药仅降到‘零关税’还不够,必须采取综合措施,从多环节、多渠道层层压减进口抗癌药品价格。”李克强强调,“要让患者及家属对急需的进口抗癌药价格降低有切实感受!”要实行多部门联动,从生产、流通、原料进口等各方面综合施策,切实把价

15天用上全新抗癌药!海南进口药械有特权

许多国人期盼的进口药物和医疗器械等医疗服务都可能以最快的速度在海南享受到。

零关税之后,进口抗癌药会更便宜吗?

导读国务院决定,2018年5月1日起,将包括抗癌药在内的所有普通药品、具有抗癌作用的生物碱类药品及有实际进口的中成药进口关税降至零,使我国实际进口的全部抗癌药实现零关税。国务院还提出将大幅降低增值税,采取政府集中采购、将进口创新药特别是急需的抗癌药及时纳入医保报销目录等方式,并研究利用跨境电商渠道,多措并举消除流通环节各种不合理加价。全文阅读大约需要3分钟,如果本文对您有任何启发,欢迎点击文末评论